|Bid||79.650 x 0|
|Ask||79.700 x 0|
|Day's Range||78.900 - 85.050|
|52 Week Range||72.100 - 148.000|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.25|
(Bloomberg) -- Shares of China’s biggest chipmaker and several of its largest pharmaceutical firms sank on Wednesday on fears that Washington will slap investment and export sanctions against more companies. Most Read from BloombergSouth Africa Hospitalization Rate Plunges in Omicron WaveBiden to Issue ‘Stark Warning’ on Vaccination Amid Covid SurgeEngland Has Hundreds of Thousands of New Omicron Cases DailyVaccine Data Gaps Point to Millions More in U.S. Who Lack ShotsThe Five-Day Office Week I
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product facility in the global network of WuXi Biologics.
Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics ("WuXi Bio") (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.